Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 238Carcinoma, Non-Small-Cell Lung 205Prostatic Neoplasms 137Lung Neoplasms 96Stomach Neoplasms 85Head and Neck Neoplasms 59Squamous Cell Carcinoma of Head and Neck 58Neoplasms 42Neoplasm Metastasis 39Esophageal Neoplasms 36Ovarian Neoplasms 29Pancreatic Neoplasms 27Sarcoma 19Urinary Bladder Neoplasms 18Adenocarcinoma of Lung 18Carcinoma, Squamous Cell 17Triple Negative Breast Neoplasms 15Nasopharyngeal Carcinoma 14Adenocarcinoma 14Carcinoma, Ovarian Epithelial 13Adenocarcinoma Of Esophagus 13Recurrence 12Inflammatory Breast Neoplasms 10Carcinoma, Transitional Cell 10Breast Neoplasms, Male 10Esophageal Squamous Cell Carcinoma 9Laryngeal Neoplasms 8Uterine Cervical Neoplasms 7Nasopharyngeal Neoplasms 7Leiomyosarcoma 7

Interventions

Pemetrexed 4pembrolizumab 3Ramucirumab 2Gemcitabine 2Carboplatin 2vistusertib 1vandetanib 1tusamitamab ravtansine 1telomerase reverse transcriptase p572Y, human 1sintilimab 1olaparib 1necitumumab 1icotinib 1durvalumab 1dacomitinib 1capivasertib 1Vinorelbine 1LY3023414 1Injections 1Immune Checkpoint Inhibitors 1Erlotinib Hydrochloride 1Drug Therapy 1Docetaxel 1Cisplatin 1Bevacizumab 1AZD4547 1AZD 8931 1AZD 6244 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Non-small Cell Lung Cancer Metastatic × Docetaxel × Clear all
NCT01703091 2019-09-30

A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer

Eli Lilly and Company

Phase 2 Completed
197 enrolled 12 charts
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡